LITS

Lite Strategy Inc
LITS

1.18 USD
+0.03
2.61%
At close Updated Mar 13, 4:00 PM EDT
Pre-market
After hours
1.20
+0.02
1.69%
1 day
2.61%
5 days
2.61%
1 month
5.36%
3 months
-22.88%
6 months
-59.45%
Year to date
-23.38%
1 year
-48.7%
5 years
-98.45%
10 years
-95.04%
 

About: Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Employees: 4

Healthcare Biotechnology
0
Funds holding %
of 8,077 funds
Explore Fund Trends
–
Analysts bullish %
See Analyst Outlook
–
Positive news %
Check Journalist POV
Price charts implemented using Lightweight Charts™